Maggie C.U. Cheang

Institute of Cancer Research — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

64h-index33.6kcitations467works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(146), HER2/EGFR in Cancer Research(110), Cancer Immunotherapy and Biomarkers(73), Cancer Genomics and Diagnostics(71), Lung Cancer Treatments and Mutations(64)

Publications466 total

Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy – results from two independent randomized trials
UNC Libraries·2025Open Access
Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
2025Open Access
Supplementary Figure S1 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
2025Open Access
Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
2025Open Access
Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
2025Open Access
Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
2025Open Access
Supplementary Figure S4 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
2025Open Access
Supplementary Table S4 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
2025Open Access
Supplementary Table S2 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
2025Open Access
Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
2025Open Access
Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
2025Open Access
Supplementary Figure S2 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
2025Open Access
Supplementary Table S3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
2025Open Access
Supplementary Figure S3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
2025Open Access
Supplementary Table S1 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
2025Open Access
Supplementary Figure S5 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
2025Open Access
Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast CancersImpact of Aromatase Inhibitors Dosing on Molecular Features
UNC Libraries·2025Open Access
222P Developing an integrated multimodal platform for the POETIC breast cancer trial
ESMO Real World Data and Digital Oncology·2025Open Access
226P In-house and commercial platforms for integrated discovery and diagnostics in pathology
ESMO Real World Data and Digital Oncology·2025Open Access
Abstract P2-01-23: A 140-gene Machine Learning Classifier Predicts Survival and Response to Chemotherapy and Immunotherapy in 2500 TNBC
Clinical Cancer Research·2025
page 1 of 24Next →

Frequent Co-authors

Torsten O. Nielsen(28), Charles M. Perou(18), David G. Huntsman(12), Samuel Leung(10), Stephen Chia(10), Joel S. Parker(9), Karen A. Gelmon(9), David Voduc(8), Matthew J. Ellis(8), Philip S. Bernard(8), Aleix Prat(8), Lisa A. Carey(7), Allen M. Gown(6), C. Blake Gilks(6), C. Blake Gilks(6), Erika Yorida(6), Dmitry Turbin(6), Sherri R. Davies(5), Chris Bajdik(5), Mitch Dowsett(5)